Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DETROL LA · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| DETROL LA (drug) | DRUG | - |
Inclusion Criteria: * Eligible participants will be females who are 18 years of age or older, with Overactive Bladder as evidenced by daily episodes of urgency without incontinence, which may be associated with frequency or nocturia but without bladder pain. At screening, eligible patients must rep...
DETROL LA is used for overactive bladder. It is a small molecule being developed by GSK plc for this condition, which falls under the therapeutic area of nephrology. The drug is currently in Phase 1 clinical development.
DETROL LA is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK. The drug is in Phase 1 clinical development for the treatment of overactive bladder.
DETROL LA is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed for this drug.
DETROL LA has one completed clinical trial, NCT00553657, titled 'The Study To Test The Effect of Standardization Of Fluid Intake In Female Patients With Overactive Bladder'. This Phase 1 trial enrolled 55 female participants aged 18 years and older in Australia.
DETROL LA is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for overactive bladder. The drug has completed one clinical trial but has not yet received regulatory approval.